Fenofibrate
- Generic Name
- Fenofibrate
- Brand Names
- Antara, Cholib, Fenoglide, Fenomax, Lipidil Supra, Lipofen, Tricor, Triglide
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21ClO4
- CAS Number
- 49562-28-9
- Unique Ingredient Identifier
- U202363UOS
- Background
Fenofibrate is a fibric acid derivative like clofibrate and gemfibrozil. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.
Fenofibrate was granted FDA approval on 31 December 1993.
- Indication
Fenofibrate is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides, and Apo B, and to increase HDL-C adults with primary hypercholesterolemia or mixed dyslipidemia. Fenofibrate is also indicated to treat adults with severe hypertriglyceridemia.
- Associated Conditions
- Mixed Dyslipidemias, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Severe Fredrickson Type IV Hypertriglyceridemia, Severe Fredrickson Type V Hypertriglyceridemia
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
- Conditions
- HypercholesterolemiaDiabetes Mellitus, Type 2HypertensionDiabetes MellitusCoronary DiseaseAtherosclerosisCardiovascular Diseases
- Interventions
- Drug: Anti-hyperglycemic AgentsDrug: Anti-hypertensive Agents
- First Posted Date
- 1999-10-28
- Last Posted Date
- 2016-11-22
- Target Recruit Count
- 10251
- Registration Number
- NCT00000620
- Locations
- 🇺🇸
Columbia University, New York, New York, United States
🇺🇸Veterans Affairs, Memphis, Tennessee, United States
🇨🇦McMaster University, Hamilton, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.